Windlas Biotech Ltd
NSE:WINDLAS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Windlas Biotech Ltd
NSE:WINDLAS
|
IN |
|
Fanli Digital Technology Co Ltd
SSE:600228
|
CN |
|
Dupont De Nemours Inc
NYSE:DD
|
US |
Windlas Biotech Ltd
Windlas Biotech Ltd. operates as a contract development and manufacturing organization (CDMO). The firm provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. The company has capabilities for both solid and liquid pharmaceutical dosage forms. The Company’s market its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. The company also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.
Windlas Biotech Ltd. operates as a contract development and manufacturing organization (CDMO). The firm provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. The company has capabilities for both solid and liquid pharmaceutical dosage forms. The Company’s market its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. The company also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.
Record Revenue: Windlas Biotech posted its highest-ever quarterly revenue for the twelfth straight quarter, with Q3 FY '26 revenue from operations up 20% year-on-year to INR 233 crores.
Strong Growth: Revenue grew 19% year-on-year for the first nine months of FY '26, signaling robust performance across business segments.
Profitability: Earnings per share for the first nine months reached INR 24.02, up 12% year-on-year. Excluding ESOP costs, 9-month EBITDA was INR 89 crores (13.3% margin) and PAT was INR 60 crores (9% margin).
Business Segments: Generic Formulations CDMO grew 23% in Q3 FY '26, Trade Generics and Institutional sales grew 7%, and Exports surged 36%, highlighting strong momentum outside India as well.
Expansion Plans: Plant 6 is on track for mechanical completion by end of FY '26, with commercialization expected in H1 FY '27. CapEx for Plant 6 is INR 50–60 crores.
Market Position: Management remains optimistic about long-term growth, citing capability building, regulatory compliance, and a focus on operational efficiency.
No US/EU Focus: Plant 6 will not target the US or Europe, remaining focused on the Indian market and other existing verticals.
